Five things for pharma marketers to know: Monday, August 31

Five things for pharma marketers to know: Monday, August 31

Kim Kardashian posts corrective information on Instagram and Twitter; DPP-4 inhibitors are linked to joint pain; doctors question off-label prescriptions of PCSK9 inhibitors

Five things for pharma marketers to know: Friday, August 28

Five things for pharma marketers to know: Friday, August 28

Amgen's Repatha receives FDA nod; Mylan shareholders vote in favor of Perrigo deal; doctors push for below-average price of experimental cancer drug

The FDA approves second PCSK9 inhibitor, Repatha

The FDA approves second PCSK9 inhibitor, Repatha

Amgen's Repatha will come to market priced $500 lower than the cost of Sanofi and Regeneron's Praluent.

Sunovion prepares for FDA decision on Aptiom

Sunovion prepares for FDA decision on Aptiom

The FDA is expected to announce this week whether it has approved the epilepsy drug as a monotherapy for partial-onset seizures.

Five things for pharma marketers to know: Thursday, August 27

Five things for pharma marketers to know: Thursday, August 27

The FDA releases biosimilar-naming draft guidance; PD1 drugs linked to a rare type of diabetes; Amgen's PCSK9 inhibitor faces approval decision

CHC and CCC partner to offer regulatory education to agencies

CHC and CCC partner to offer regulatory education to agencies

The compliance "university" aims to help healthcare agencies and publishers stay up to date on the latest regulatory changes.

Five things for pharma marketers to know: Wednesday, August 26

Five things for pharma marketers to know: Wednesday, August 26

Medicaid officials urged to expand access to hepatitis-C drugs; Perrigo is looking to make acquisitions; Sarepta's experimental therapy gets priority review

Diabetes device firm Intarcia taps former ICC Lowe CEO Viviano as marketing lead

Diabetes device firm Intarcia taps former ICC Lowe CEO Viviano as marketing lead

Longtime ICC leader Viviano moves to the client side to help the start-up build its marketing team and become a commercial contender.


Email Newsletters


Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.